If you could vote on Brexit now which option would you choose?
   

JPM: Gilead's Veklury, now used in half of hospitalized U.S. COVID-19 patients, delivers multibillion-dollar revenue bump


Gilead Sciences unveiled a surprise Monday: It enjoyed a bigger-than-expected sales boost from COVID-19 therapy Veklury, better known as remdesivir. But what changed since October, when Gilead last predicted 2020 sales? Hospitalizations are up fourfold, for one—and Veklury use is way up, too. “One in two patients hospitalized now is treated with Veklury in the United States,” CEO Dan O’Day said during Gilead’s Monday presentation at the annual J.P. Morgan healthcare conference, noting that Veklury use in hospitalized COVID-19 patients is up from 30% in October to around 50% to 60% today.

FiercePharma - January 12, 2021

View the full story here: https://www.fiercepharma.com/pharma/jpm-gilead-s-veklury-now-used-half-hospitalized-u-s-covid-patients-delivers-big-revenue-bump